Skip to content

Alumis Inc. ALMS Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Amgen logo
AmgenAMGN
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
Immunome logo
ImmunomeIMNM

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.17B+739%

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s software and technology licenses, net?
Alumis Inc. (ALMS) reported software and technology licenses, net of $6.83M in Q1 2026.
How has Alumis Inc.'s software and technology licenses, net changed year-over-year?
Alumis Inc.'s software and technology licenses, net increased by 15080.0% year-over-year, from $45K to $6.83M.
What is the long-term trend for Alumis Inc.'s software and technology licenses, net?
Over 2 years (2023 to 2025), Alumis Inc.'s software and technology licenses, net has grown at a 2896.9% compound annual growth rate (CAGR), from $7K to $6.29M.